1. Werner Syndrome Helicase Has a Critical Role in DNA Damage Responses in the Absence of a Functional Fanconi Anemia Pathway
- Author
-
Monika Aggarwal, Chiara Iannascoli, Taraswi Banerjee, Pietro Pichierri, Joshua A. Sommers, Robert M. Brosh, and Robert H. Shoemaker
- Subjects
DNA Replication ,Alkylating Agents ,congenital, hereditary, and neonatal diseases and abnormalities ,Cancer Research ,Werner Syndrome Helicase ,Fanconi anemia, complementation group C ,DNA Repair ,DNA damage ,Mitomycin ,Blotting, Western ,RAD51 ,Apoptosis ,Ataxia Telangiectasia Mutated Proteins ,DNA-Activated Protein Kinase ,Article ,Maleimides ,Fanconi anemia ,Chromosomal Instability ,medicine ,Humans ,DNA Breaks, Double-Stranded ,Enzyme Inhibitors ,RNA, Small Interfering ,education ,Cell Proliferation ,Werner syndrome ,education.field_of_study ,RecQ Helicases ,biology ,Nuclear Proteins ,nutritional and metabolic diseases ,Helicase ,Drug Synergism ,HCT116 Cells ,medicine.disease ,Molecular biology ,Chromatin ,enzymes and coenzymes (carbohydrates) ,Exodeoxyribonucleases ,Fanconi Anemia ,Oncology ,biology.protein ,Cancer research ,Drug Therapy, Combination ,Rad51 Recombinase ,Homologous recombination ,HeLa Cells - Abstract
Werner syndrome is genetically linked to mutations in WRN that encodes a DNA helicase-nuclease believed to operate at stalled replication forks. Using a newly identified small-molecule inhibitor of WRN helicase (NSC 617145), we investigated the role of WRN in the interstrand cross-link (ICL) response in cells derived from patients with Fanconi anemia, a hereditary disorder characterized by bone marrow failure and cancer. In FA-D2−/− cells, NSC 617145 acted synergistically with very low concentrations of mitomycin C to inhibit proliferation in a WRN-dependent manner and induce double-strand breaks (DSB) and chromosomal abnormalities. Under these conditions, ataxia–telangiectasia mutated activation and accumulation of DNA-dependent protein kinase, catalytic subunit pS2056 foci suggested an increased number of DSBs processed by nonhomologous end-joining (NHEJ). Rad51 foci were also elevated in FA-D2−/− cells exposed to NSC 617145 and mitomycin C, suggesting that WRN helicase inhibition interferes with later steps of homologous recombination at ICL-induced DSBs. Thus, when the Fanconi anemia pathway is defective, WRN helicase inhibition perturbs the normal ICL response, leading to NHEJ activation. Potential implication for treatment of Fanconi anemia–deficient tumors by their sensitization to DNA cross-linking agents is discussed. Cancer Res; 73(17); 5497–507. ©2013 AACR.
- Published
- 2013